AP 18Reversible TRPA1 channel blocker CAS# 55224-94-7 |
2D Structure
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Tinidazole
Catalog No.:BCC4866
CAS No.:19387-91-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 55224-94-7 | SDF | Download SDF |
PubChem ID | 9584673 | Appearance | Powder |
Formula | C11H12ClNO | M.Wt | 209.67 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | (NE)-N-[(E)-4-(4-chlorophenyl)-3-methylbut-3-en-2-ylidene]hydroxylamine | ||
SMILES | CC(=CC1=CC=C(C=C1)Cl)C(=NO)C | ||
Standard InChIKey | MHTJEUOFLVQMCL-NJHPPEEMSA-N | ||
Standard InChI | InChI=1S/C11H12ClNO/c1-8(9(2)13-14)7-10-3-5-11(12)6-4-10/h3-7,14H,1-2H3/b8-7+,13-9+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Reversible TRPA1 channel blocker (IC50 values are 3.1 and 4.5 μM at human and mouse TRPA1 respectively). Blocks cinnameldehyde-induced but not capsaicin-induced nociception and reverses mechanical hyperalgesia in vivo. Also blocks TRPA1 pore dilation (IC50 = 10.3 μM for the inhibition of Yo-Pro uptake). |
AP 18 Dilution Calculator
AP 18 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.7694 mL | 23.847 mL | 47.694 mL | 95.388 mL | 119.235 mL |
5 mM | 0.9539 mL | 4.7694 mL | 9.5388 mL | 19.0776 mL | 23.847 mL |
10 mM | 0.4769 mL | 2.3847 mL | 4.7694 mL | 9.5388 mL | 11.9235 mL |
50 mM | 0.0954 mL | 0.4769 mL | 0.9539 mL | 1.9078 mL | 2.3847 mL |
100 mM | 0.0477 mL | 0.2385 mL | 0.4769 mL | 0.9539 mL | 1.1923 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AP-18 is a selective channel blocker which can reversibly inhibit TRPA1 of human and mouse with IC50 of 3.1 µM and 4.5 µM, respectively.
TRPV1 belongs to the transient receptor potential family of cation channels and is activated by low pH, heat, and capsaicin. Originally known as a noxious cold-activated ion channel, TRPA1 is expressed in the same sensory neurons as TRPV1 and is activated directly by a variety of chemicals via covalent modification, and indirectly through G-protein coupled receptors.
In odontoblasts, AP18 is effective to inhibit the increase in intracellular Ca2+ concentration induced by allyl isothiocyanate and cinnamaldehyde (the TRPA1 agonists) 1.
In vivo, AP-18 blocks the transient receptor potential ankyrin 1 receptors and can reduce chronic pain associated with arthritis. This product is also capable to induce cinnamaldehyde-induced nociception and to block cold- and mustard oil-induced activation of mouse TRPA1 but not capsaicin-induced activation 2. In addition, AP18 treatment reversed CFA-induced mechanical hyperalgesia in mice 2. Thus, TRPA1 is essential for sensitization of nociception.
References:
1. Egbuniwe O, Grover S, Duggal AK, et al. TRPA1 and TRPV4 activation in human odontoblasts stimulates ATP release. Journal of dental research. 2014;93(9):911-917.
2. Petrus M, Peier AM, Bandell M, et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Molecular pain. 2007;3:40.
- Dexamethasone Sodium Phosphate
Catalog No.:BCC4557
CAS No.:55203-24-2
- Sasapyrine
Catalog No.:BCC4714
CAS No.:552-94-3
- Daidzin
Catalog No.:BCN5891
CAS No.:552-66-9
- Prunetin
Catalog No.:BCN2335
CAS No.:552-59-0
- Eriodictyol
Catalog No.:BCN1209
CAS No.:552-58-9
- Isorhoifolin
Catalog No.:BCN5739
CAS No.:552-57-8
- Paeonol
Catalog No.:BCN5738
CAS No.:552-41-0
- Oxohydrastinine
Catalog No.:BCN3299
CAS No.:552-29-4
- Kaempferol 3-sophoroside-7-glucoside
Catalog No.:BCN7825
CAS No.:55136-76-0
- (S)-3-Carboxy-4-hydroxyphenylglycine
Catalog No.:BCC6607
CAS No.:55136-48-6
- 4beta-Carboxy-19-nortotarol
Catalog No.:BCN4065
CAS No.:55102-39-1
- 2'-Aminoacetophenone
Catalog No.:BCN1746
CAS No.:551-93-9
- Rolapitant
Catalog No.:BCC6441
CAS No.:552292-08-7
- Vallesiachotamine
Catalog No.:BCN3548
CAS No.:5523-37-5
- T16Ainh - A01
Catalog No.:BCC6220
CAS No.:552309-42-9
- A-443654
Catalog No.:BCC1321
CAS No.:552325-16-3
- A-674563
Catalog No.:BCC3903
CAS No.:552325-73-2
- Boc-Gln(Xan)-OH
Catalog No.:BCC3385
CAS No.:55260-24-7
- MnTBAP Chloride
Catalog No.:BCC6477
CAS No.:55266-18-7
- Praziquantel
Catalog No.:BCC4829
CAS No.:55268-74-1
- Atractylodin
Catalog No.:BCN6292
CAS No.:55290-63-6
- (Z)-Falcarindiol
Catalog No.:BCN8495
CAS No.:55297-87-5
- Tiamulin
Catalog No.:BCC9179
CAS No.:55297-95-5
- Thonzonium Bromide
Catalog No.:BCC5636
CAS No.:553-08-2
Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation.[Pubmed:20693392]
Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1242-54.
IL-18 and the extracellular matrix metalloproteinase (MMP) inducer (EMMPRIN) stimulate the expression of proinflammatory cytokines and MMPs and are elevated in myocardial hypertrophy, remodeling, and failure. Here, we report several novel findings in primary cardiomyocytes treated with IL-18. First, IL-18 activated multiple transcription factors, including NF-kappaB (p50 and p65), activator protein (AP)-1 (cFos, cJun, and JunD), GATA, CCAAT/enhancer-binding protein, myocyte-specific enhancer-binding factor, interferon regulatory factor-1, p53, and specific protein (Sp)-1. Second, IL-18 induced EMMPRIN expression via myeloid differentiation primary response gene 88/IL-1 receptor-associated kinase/TNF receptor-associated factor-6/JNK-dependent Sp1 activation. Third, IL-18 induced a number of MMP genes, particularly MMP-9, at a rapid rate as well as tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-3 at a slower rate. Finally, the IL-18 induction of MMP-9 was mediated in part via EMMPRIN and through JNK- and ERK-dependent AP-1 activation and p38 MAPK-dependent NF-kappaB activation. These results suggest that the elevated expression of IL-18 during myocardial injury and inflammation may favor EMMPRIN and MMP induction and extracellular matrix degradation. Therefore, targeting IL-18 or its signaling pathways may be of potential therapeutic benefit in adverse remodeling.
Smooth muscle-depressant activity of AP-18, a putative TRPA1 antagonist in the guinea pig intestine.[Pubmed:25247599]
Pharmacology. 2014;94(3-4):131-4.
AP-18, a putative antagonist at TRPA1 receptor/ion channel, caused smooth muscle relaxation at 10-100 micromol/l. It inhibited cholinergic twitch responses evoked by electrical field stimulation of cholinergic nerves as well as contractions in response to acetylcholine and histamine in the guinea pig small intestine. AP-18 (30 micromol/l) blocked spontaneous contractions of longitudinal strips of human jejunum. It is concluded that AP-18 may have limited value in studying TRPA1-mediated responses in smooth muscles and should probably be used with care in other preparations because of possible nonspecific effects.
EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling.[Pubmed:20538003]
J Mol Cell Cardiol. 2010 Oct;49(4):655-63.
The transmembrane glycoprotein extracellular matrix metalloproteinase inducer (EMMPRIN), and the pleiotropic proinflammatory cytokine interleukin (IL)-18, play critical roles in myocardial remodeling, by inducing matrix degrading metalloproteinases (MMPs). Previously we showed that IL-18 induces EMMPRIN expression in cardiomyocytes via MyD88/IRAK4/TRAF6/JNK-dependent Sp1 activation. Here in reciprocal studies we demonstrate that EMMPRIN is a potent inducer of IL-18 transcription, protein expression and protein secretion in primary mouse cardiomyocytes. We show for the first time that EMMPRIN stimulates the activation of NF-kappaB, AP-1, CREB, and ATF-2 in cardiomyocytes, and induces IL-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB and MKK7/JNK/AP-1 signaling. Moreover, EMMPRIN induces robust time-dependent induction of various MMP mRNAs. EMMPRIN also induces the mRNA of TIMPs 1 and 3, but in a delayed fashion. These results suggest that IL-18-induced EMMPRIN expression may favor net MMP expression and ECM destruction, and thus identify both as potential therapeutic targets in countering adverse myocardial remodeling.
Pore dilation occurs in TRPA1 but not in TRPM8 channels.[Pubmed:19159452]
Mol Pain. 2009 Jan 21;5:3.
Abundantly expressed in pain-sensing neurons, TRPV1, TRPA1 and TRPM8 are major cellular sensors of thermal, chemical and mechanical stimuli. The function of these ion channels has been attributed to their selective permeation of small cations (e.g., Ca2+, Na+ and K+), and the ion selectivity has been assumed to be an invariant fingerprint to a given channel. However, for TRPV1, the notion of invariant ion selectivity has been revised recently. When activated, TRPV1 undergoes time and agonist-dependent pore dilation, allowing permeation of large organic cations such as Yo-Pro and NMDG+. The pore dilation is of physiological importance, and has been exploited to specifically silence TRPV1-positive sensory neurons. It is unknown whether TRPA1 and TRPM8 undergo pore dilation. Here we show that TRPA1 activation by reactive or non-reactive agonists induces Yo-Pro uptake, which can be blocked by TRPA1 antagonists. In outside-out patch recordings using NMDG+ as the sole external cation and Na+ as the internal cation, TRPA1 activation results in dynamic changes in permeability to NMDG+. In contrast, TRPM8 activation does not produce either Yo-Pro uptake or significant change in ion selectivity. Hence, pore dilation occurs in TRPA1, but not in TRPM8 channels.
Nitrooleic acid, an endogenous product of nitrative stress, activates nociceptive sensory nerves via the direct activation of TRPA1.[Pubmed:19171673]
Mol Pharmacol. 2009 Apr;75(4):820-9.
Transient Receptor Potential A1 (TRPA1) is a nonselective cation channel, preferentially expressed on a subset of nociceptive sensory neurons, that is activated by a variety of reactive irritants via the covalent modification of cysteine residues. Excessive nitric oxide during inflammation (nitrative stress), leads to the nitration of phospholipids, resulting in the formation of highly reactive cysteine modifying agents, such as nitrooleic acid (9-OA-NO(2)). Using calcium imaging and electrophysiology, we have shown that 9-OA-NO(2) activates human TRPA1 channels (EC(50), 1 microM), whereas oleic acid had no effect on TRPA1. 9-OA-NO(2) failed to activate TRPA1 in which the cysteines at positions 619, 639, and 663 and the lysine at 708 had been mutated. TRPA1 activation by 9-OA-NO(2) was not inhibited by the NO scavenger carboxy-PTIO. 9-OA-NO(2) had no effect on another nociceptive-specific ion channel, TRPV1. 9-OA-NO(2) activated a subset of mouse vagal and trigeminal sensory neurons, which also responded to the TRPA1 agonist allyl isothiocyanate and the TRPV1 agonist capsaicin. 9-OA-NO(2) failed to activate neurons derived from TRPA1(-/-) mice. The action of 9-OA-NO(2) at nociceptive nerve terminals was investigated using an ex vivo extracellular recording preparation of individual bronchopulmonary C fibers in the mouse. 9-OA-NO(2) evoked robust action potential discharge from capsaicin-sensitive fibers with slow conduction velocities (0.4-0.7 m/s), which was inhibited by the TRPA1 antagonist AP-18. These data demonstrate that nitrooleic acid, a product of nitrative stress, can induce substantial nociceptive nerve activation through the selective and direct activation of TRPA1 channels.
A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition.[Pubmed:18086313]
Mol Pain. 2007 Dec 17;3:40.
Mechanical hyperalgesia is a clinically-relevant form of pain sensitization that develops through largely unknown mechanisms. TRPA1, a Transient Receptor Potential ion channel, is a sensor of pungent chemicals that may play a role in acute noxious mechanosensation and cold thermosensation. We have developed a specific small molecule TRPA1 inhibitor (AP18) that can reduce cinnameldehyde-induced nociception in vivo. Interestingly, AP18 is capable of reversing CFA-induced mechanical hyperalgesia in mice. Although TRPA1-deficient mice develop normal CFA-induced hyperalgeisa, AP18 is ineffective in the knockout mice, consistent with an on-target mechanism. Therefore, TRPA1 plays a role in sensitization of nociception, and that compensation in TRPA1-deficient mice masks this requirement.